ethyl 4-(4-fluorophenylsulfonyl)piperidine-4-carboxylate hydrochloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: ethyl 4-(4-fluorophenylsulfonyl)piperidine-4-carboxylate hydrochloride
• 英文别名: Ethyl 4-(4-fluorophenyl)sulfonylpiperidine-4-carboxylate;hydrochloride
• 化学式: C₁₄H₁₈FNO₄S*ClH
• 分子量: 351.827
• InChiKey: SCFUXIXFDOOVDM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.71
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  80.8
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl 4-(4-fluorophenylsulfonyl)piperidine-4-carboxylate hydrochloride 在 potassium carbonate 、 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 生成 Ethyl 4-(4-phenylsulfanylphenyl)sulfonyl-1-prop-2-ynylpiperidine-4-carboxylate
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of β- and α-Piperidine Sulfone Hydroxamic Acid Matrix Metalloproteinase Inhibitors with Oral Antitumor Efficacy

  摘要：

  alpha-Piperidine-beta-sulfone hydroxamate derivatives were explored that are potent for matrix metalloproteinases (MMP)-2, -9, and -13 and are sparing of MMP-1. The investigation of the beta-sulfones subsequently led to the discovery of hitherto unknown alpha-sulfone hydroxamates that are superior to the corresponding beta-sulfones in potency for target MMPs, selectivity vs MMP-1, and exposure when dosed orally. alpha-Tiperidine-alpha-sulfone, hydroxamate 35f (SC-276) was advanced through antitumor and antiangiogenesis assays and was selected for development. Compound 35f demonstrates excellent antitumor activity vs MX-1 breast tumor in mice when dosed orally as monotherapy or in combination with paclitaxel.

  DOI：

  10.1021/jm0500875
• 作为产物：
  描述：

  N-Boc-4-哌啶甲酸乙酯 在 盐酸 、 间氯过氧苯甲酸 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙酸乙酯 为溶剂， 反应 45.5h， 生成 ethyl 4-(4-fluorophenylsulfonyl)piperidine-4-carboxylate hydrochloride
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of β- and α-Piperidine Sulfone Hydroxamic Acid Matrix Metalloproteinase Inhibitors with Oral Antitumor Efficacy

  摘要：

  alpha-Piperidine-beta-sulfone hydroxamate derivatives were explored that are potent for matrix metalloproteinases (MMP)-2, -9, and -13 and are sparing of MMP-1. The investigation of the beta-sulfones subsequently led to the discovery of hitherto unknown alpha-sulfone hydroxamates that are superior to the corresponding beta-sulfones in potency for target MMPs, selectivity vs MMP-1, and exposure when dosed orally. alpha-Tiperidine-alpha-sulfone, hydroxamate 35f (SC-276) was advanced through antitumor and antiangiogenesis assays and was selected for development. Compound 35f demonstrates excellent antitumor activity vs MX-1 breast tumor in mice when dosed orally as monotherapy or in combination with paclitaxel.

  DOI：

  10.1021/jm0500875

文献信息

• Aromatic sulfone hydroxamates and their use as protease inhibitors
  申请人：——

  公开号：US20040010019A1

  公开（公告）日：2004-01-15

  This invention is directed to aromatic sulfone hydroxamates (also known as “aromatic sulfone hydroxamic acids”) and salts thereof that, inter alia, inhibit matrix metalloproteinase (also known as “matrix metalloprotease” or “MMP”) activity and/or aggrecanase activity. This invention also is directed to a prevention or treatment method that comprises administering such a compound or salt in an MMP-inhibiting and/or aggrecanase-inhibiting effective amount to an animal, particularly a mammal having (or disposed to having) a pathological condition associated with MMP and/or aggrecanase activity.

  这项发明涉及芳香砜羟肟酸酯（也称为“芳香砜羟肟酸”）及其盐，该化合物在抑制基质金属蛋白酶（也称为“基质金属蛋白酶”或“MMP”）活性和/或聚集素酶活性方面具有作用。该发明还涉及一种预防或治疗方法，包括向动物，特别是患有（或易患）与MMP和/或聚集素酶活性相关的病理状况的哺乳动物，施用此类化合物或盐以达到抑制MMP和/或聚集素酶的有效量。
• Carborane‐Containing Matrix Metalloprotease (MMP) Ligands as Candidates for Boron Neutron‐Capture Therapy (BNCT)
  作者：Marlon R. Lutz、Sebastian Flieger、Andre Colorina、John Wozny、Narayan S. Hosmane、Daniel P. Becker

  DOI：10.1002/cmdc.202000470

  日期：2020.10.19

  potent and selective sulfone hydroxamate inhibitors SC‐76276, SC‐78080 (SD‐2590), and SC‐77964, potent MMP inhibitors have been designed and synthesized to append a boron‐rich carborane cluster by employing click chemistry to target tumor cells that are known to upregulate gelatinases. Docking against MMP‐2 suggests binding involving the hydroxamate zinc‐binding group, key H‐bonds by the sulfone moiety

  基于先前报道的强效选择性砜异羟肟酸酯抑制剂 SC-76276、SC-78080 (SD-2590) 和 SC-77964，已经设计并合成了有效的 MMP 抑制剂，通过点击化学添加富硼碳硼烷簇靶向已知上调明胶酶的肿瘤细胞。与 MMP-2 对接表明结合涉及异羟肟酸锌结合基团、砜部分与肽骨架残基 Leu82 和 Leu83 的关键 H 键，以及与深 P1' 口袋的疏水相互作用。两种三唑区域异构体中更有效的一种的 IC 50与 MMP-2 相比为 3.7 nM，IC 50与 MMP-9 相比为 46 nM。
• [EN] CARBORANE HYDROXAMIC ACID MATRIX METALLOPROTEINASE INHIBITORS AND AGENTS FOR BORON NEUTRON CAPTURE THERAPY<br/>[FR] INHIBITEURS DE MÉTALLOPROTÉINASE MATRICIELLE D'ACIDE HYDROXAMIQUE CARBORANE ET AGENTS POUR UNE THÉRAPIE PAR CAPTURE DE NEUTRONS PAR LE BORE
  申请人：UNIV LOYOLA CHICAGO

  公开号：WO2020006384A1

  公开（公告）日：2020-01-02

  Disclosed herein are novel carborane hydroxamic acid matrix metalloproteinase ("MMP") inhibitors and agents bearing borane-containing moieties and methods for their use in treating or preventing a disease, such as cancer and rheumatoid arthritis. In particular, disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salt thereof: Formula (I) wherein the substituents are as described.

  本文披露了新型碳硼烷羟肟酸基金属蛋白酶抑制剂和含硼基团的药物，以及它们在治疗或预防疾病（如癌症和类风湿性关节炎）中的使用方法。具体来说，本文披露了化合物的结构式（I）及其药用盐：结构式（I）中的取代基如所述。
• [EN] AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR<br/>[FR] INHIBITEUR DE METALLOPROTEASE A BASE D'ACIDE HYDROXAMIQUE AROMATIQUE SULFONÉ
  申请人：SEARLE & CO

  公开号：WO2000050396A1

  公开（公告）日：2000-08-31

  A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9 and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a condition associated with pathological matrix metalloprotease activity. Also disclosed are metalloprotease inhibitor compounds having those selective activities, processes for manufacture of such compounds and pharmaceutical compositions using an inhibitor.

  本发明公开了一种治疗过程，包括向患有与病理性基质金属蛋白酶活性相关的疾病的宿主施用一种具有出色抑制活性的芳香基磺酮羟肟酸的有效量，例如MMP-2、MMP-9和MMP-13，同时对至少MMP-1的抑制作用明显较小。此外，还公开了具有这些选择性活性的金属蛋白酶抑制剂化合物，制造这种化合物的过程以及使用抑制剂的制药组合物。
• AROMATIC SULFONE HYDROXAMIC ACID METALLOPROTEASE INHIBITOR
  申请人：——

  公开号：US20010014688A1

  公开（公告）日：2001-08-16

  A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9 and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a condition associated with pathological matrix metalloprotease activity. Also disclosed are metalloprotease inhibitor compounds having those selective activities, processes for manufacture of such compounds and pharmaceutical compositions using an inhibitor.

  本发明涉及一种治疗过程，包括向患有与病理基质金属蛋白酶活性相关的状况的宿主施用有效量的芳香磺酮羟肟酸，该芳香磺酮羟肟酸表现出优异的抑制活性，可抑制一种或多种基质金属蛋白酶(MMP)酶，如MMP-2、MMP-9和MMP-13，同时对MMP-1的抑制显著较少。还揭示了具有这些选择性活性的金属蛋白酶抑制剂化合物、制造这种化合物的工艺以及使用抑制剂的制药组合物。